NLNi Li

Ni Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ni Li has a total of 24 co-authors. Here are the top co-authors by number of shared publications:

  • Bo Lei

    China Telecom Corporation Limited Research Institute, Beijing, China

    1 shared publication
  • Dan Zhao

    State Key Laboratory of Oral Diseases National Clinical Research Center for Oral Diseases West China Hospital of Stomatology Sichuan University Chengdu 610041 China

    1 shared publication
  • Hang Lv

    China Telecom Corporation Limited Research Institute, Beijing, China

    1 shared publication
  • Hao-Tian Xiang

    Department of Ophthalmology, West China Hospital, Sichuan University, Chengdu, China

    1 shared publication
  • Hong Lin

    Department of Ophthalmology, West China Hospital, Sichuan University, Chengdu, China

    1 shared publication
  • Hongmei Luo

    Department of Ophthalmology, West China Hospital, Sichuan University, Guoxue Lane37, Chengdu, Sichuan, People's Republic of China.

    1 shared publication

Latest Publications

  • Open Access

    Micro‐Focused Ultrasound Treatment for Periocular Skin Leading to Corneal Leukoma With Iridocyclitis: A Case Report

    by Jie Liu, Hongmei Luo, Ni Li

    Background: Micro‐focused ultrasound (MFUS) converts the mechanical energy of high‐frequency vibrations into thermal energy and induces collagen remodeling through thermal effects to achieve skin tightening and lifting. However, when employed for periocular skin treatment, MFUS carries a potential risk of ocular injury, which deserves high attention from cosmetic surgeons. Aims: This article reports a case of a young female patient who developed transient visual acuity decline with iridocyclitis and residual corneal leukoma after MFUS treatment on the periocular skin. Patient: A 32‐year‐old female patient underwent facial MFUS treatment at a cosmetic clinic to improve facial skin laxity. During the treatment of the right periocular skin, the patient developed right eye pain and visual acuity decline. The patient was treated with nonsteroidal anti‐inflammatory drugs (NSAIDs) and glucocorticoids in the right eye and followed up for 3 months. The visual acuity of the right eye improved, but a permanent corneal leukoma persisted. Results: While MFUS treatment targeting the periorbital area can improve skin laxity, it poses a risk of corneal injury and iridocyclitis. After the treatment, the iridocyclitis resolved, but a permanent corneal leukoma remained. Conclusions: Periocular MFUS treatment carries the risk of irreversible thermal damage to ocular tissues. Cosmetic surgeons must strictly determine the intensity threshold for periocular MFUS and ensure proper application of eye‐protective devices.


  • Outcomes of laser peripheral iridotomy in subgroups of primary angle closure disease eyes according to swept-source optical coherence tomography parameters

    by Le-Feng Wang, Hao-Tian Xiang, Si-Jie Chen, Shan-Ming Jiang, Jia-Ying Zhang, Xue-Lin Tang, Hong Lin, Ni Li

    Aims This study aimed to examine the impact of laser peripheral iridotomy (LPI) on subgroups of primary angle closure eyes based on swept-source optical coherence tomography (SS-OCT). Methods SS-OCT was used to image 115 eyes with primary angle-closure disease (PACD) at prior to LPI, 1 week, 4 weeks and 12 weeks after LPI. A hierarchical cluster analysis was conducted to classify PACD eyes into subgroups based on pre-LPI SS-OCT parameters. The primary parameters were then compared after LPI to assess any variations in the outcomes among the identified subgroups. A mixed-effects model was used to evaluate the difference between subgroups and the effect of LPI. Results The hierarchical cluster analysis resulted in the identification of two distinct clusters. Cluster 1 (56 eyes) exhibited larger lens vault, pupil distance, iris volume, iris area, iris thickness 2000, as well as narrower angles (p < 0.05 for all). Cluster 2 (59 eyes) had smaller anterior chamber width and anterior chamber volume (p < 0.05 for all). Following LPI, there was an observed increase in the angle size and a decrease in irido-trabecular contact index (ITCI) in both clusters (p < 0.05 for all). Over a period of 3 months, the cluster 1 exhibited stability in angle size and ITCI, whereas cluster 2 exhibited a gradual decline in angle size and a gradual increase in ITCI (p < 0.05 for all). Conclusion This study successfully identified two distinct subgroups of PACD eyes based on SS-OCT parameters. Smaller eyes demonstrated a declining response to LPI over a period of 3 months.

  • The Neuroprotective Effect of MicroRNA‐22‐3p Modified Tetrahedral Framework Nucleic Acids on Damaged Retinal Neurons Via TrkB/BDNF Signaling Pathway

    by Jiajie Li, Lirong Xiao, Naihong Yan, Yanjing Li, Yun Wang, Xin Qin, Dan Zhao, Mengting Liu, Ni Li, Yunfeng Lin

    Glaucoma is the world's leading irreversible cause of blindness. It is characterized by progressive retinal ganglion cells (RGCs) loss and axon damage, and there is no effective prevention or treatment so far. In this study, tetrahedral frame nucleic acids (tFNAs) with various biological functions are selected as the carrier, and microRNA‐22‐3p (miR‐22) are modified by attaching them onto tFNAs to synthesize a novel DNA nanocomplex (tFNAs‐miR22). Relevant results show that tFNAs can efficiently transfer miR‐22 into damaged retinal neurons to impose a neuroprotective effect on glaucoma. More interestingly, a certain synergism between tFNAs and miR‐22 is shown. tFNAs‐miR22 can selectively activate tyrosine kinase receptor B (TrkB) and regulate the TrkB‐brain‐derived growth factor (BDNF) signaling pathway to restore the expression of BDNF on the models of N‐methyl‐D‐aspartate (NMDA)‐induced glaucoma in vivo and in vitro, thus exerting the neuroprotective effect on retinal neurons. This study shows the successfully establishment of a simple but effective delivery system of microRNAs associated with glaucoma treatment, which may be a promising neuroprotective agent for future treatment of this optic neurodegenerative disease.